{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/management/preconception-or-pregnant/","result":{"pageContext":{"chapter":{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant","depth":2,"htmlHeader":"<!-- begin field eaed6490-2358-4d9c-b05e-672fc34abcab --><h2>Scenario: Preconception or pregnant</h2><!-- end field eaed6490-2358-4d9c-b05e-672fc34abcab -->","summary":"Covers the management of women planning a pregnancy or who are pregnant, who have pre-existing subclinical or overt hypothyroidism, or are newly diagnosed with subclinical or overt hypothyroidism.","htmlStringContent":"<!-- begin item 271d2b80-2dbc-4547-8275-4374a4ba5540 --><!-- begin field 42fac470-6890-407f-a88b-acbc01564677 --><p>From age 18 years onwards (Female).</p><!-- end field 42fac470-6890-407f-a88b-acbc01564677 --><!-- end item 271d2b80-2dbc-4547-8275-4374a4ba5540 -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5ae6a337-ed27-5737-84c2-6b41cbe0014d","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field edbba617-0e55-4cd1-adf5-7e194d8f2023 --><h3>How should I manage a woman who is preconception or pregnant?</h3><!-- end field edbba617-0e55-4cd1-adf5-7e194d8f2023 -->","summary":null,"htmlStringContent":"<!-- begin item d5c95bd6-187e-47ac-9efc-9eb935a9ad77 --><!-- begin field b52963db-c5b6-4807-a2a8-ee4b1696c5f4 --><p><strong>Arrange a referral to an endocrinology specialist for all women with overt or subclinical hypothyroidism who are:</strong></p><ul><li><strong>Planning a pregnancy</strong><ul><li>Check thyroid function tests (TFTs) before conception if possible.</li><li>If TFTs are not within the euthyroid range, advise delaying conception and using contraception until the woman is stabilised on levothyroxine (LT4) treatment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.<ul><li>Discuss with an endocrinologist if there is any uncertainty about initiation of treatment or what dose to prescribe while waiting for specialist review.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/levothyroxine/#initiation-titration\">Initiation and titration</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/\">Prescribing information</a> for detailed information on the initiation and titration of LT4 therapy.</li></ul></li><li>Check that the woman understands there is likely to be an increased demand for LT4 treatment during pregnancy, and her dose of LT4 must be adjusted as early as possible in pregnancy to reduce the chance of obstetric and neonatal <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/complications/\">complications</a>.</li><li>Advise the woman to seek immediate medical advice if pregnancy is suspected or confirmed.</li><li>Offer advice on sources of information and support, such as the British Thyroid Foundation leaflet <a data-hyperlink-id=\"f9af1b49-47e3-4ae1-986b-ab500099b9f4\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=941f817e-a8da-4ea9-8ee9-83772477c280\" target=\"_blank\">Your guide to pregnancy and fertility in thyroid disorders</a>.</li></ul></li><li><strong>Pregnant</strong><ul><li>Check TFTs immediately once pregnancy is confirmed, and interpret results using a pregnancy-related reference range.</li><li>Discuss urgently with an endocrinologist regarding initiation of, or changes to, dosage of LT4 and TFT monitoring while waiting for specialist review.</li></ul></li></ul><!-- end field b52963db-c5b6-4807-a2a8-ee4b1696c5f4 --><!-- end item d5c95bd6-187e-47ac-9efc-9eb935a9ad77 -->","subChapters":[{"id":"5e8e398c-24ec-500b-912f-71f207ae042e","slug":"basis-for-recommendation-601","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f4353a50-b5f5-4fdf-9aa6-94d8b81396c8 --><h4>Basis for recommendation</h4><!-- end field f4353a50-b5f5-4fdf-9aa6-94d8b81396c8 -->","summary":null,"htmlStringContent":"<!-- begin item 6018a63c-4aa2-45e9-bace-a3ddc163046a --><!-- begin field 4dab0ec2-4fab-4e0d-8805-05e07939bac3 --><div>The recommendations on management of women who are planning a pregnancy or are pregnant are based on the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>], the British Thyroid Association (BTA) statement <em>Management of primary hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>], the European Thyroid Association (ETA) <em>Guidelines for the management of subclinical hypothyroidism in pregnancy and in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>], the American Thyroid Association (ATA) <em>Guidelines for the treatment of hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>] and <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>], a meta-analysis of the impact of subclinical hypothyroidism and thyroid hormone treatment during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Maraka, 2016</a>], and expert opinion in review articles on hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Gaitonde et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</div><h5>Advice for women pre-pregnancy</h5><ul><li>The recommendation to check thyroid function tests (TFTs) pre-conception is based on the fact the level of thyroid-stimulating hormone (TSH) can influence the speed and extent of levothyroxine (LT4) dose increases needed to maintain a euthyroid state during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>The aim to conceive when TFTs are stable is based on the ATA guidelines on pregnancy and the postpartum, which advise that all women treated with LT4 pre-conception have TFTs optimized pre-pregnancy to reduce the need for large LT4 dose increases during pregnancy, and reduce the risk of TSH elevation during the first trimester particularly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>]. This approach is supported by the ETA guidelines for the management of subclinical hypothyroidism in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>].</li><li>The recommendation to seek immediate medical advice if pregnancy is suspected or confirmed is due to the increased LT4 dose requirements after conception [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li></ul><h5>Advice for women who are pregnant</h5><ul><li>The recommendation to use pregnancy-related reference ranges to interpret TFTs in pregnancy is based on the ETA guidelines on the management of subclinical hypothyroidism in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>].<ul><li>As the median TSH level is lower in the first trimester of pregnancy when compared with the non-pregnant reference range, trimester-specific reference ranges are recommended to avoid misclassification of thyroid dysfunction during pregnancy.</li></ul></li><li>The information on the likely increased demands for LT4 treatment during pregnancy are based on the Endocrine Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>], the ETA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>], the ATA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].<ul><li>Women with known thyroid dysfunction who are taking LT4 may need the dose increased by 30–50% to maintain euthyroidism from as early as 4–6 weeks' gestation, for optimal fetal growth and development, with the need for regular TFT monitoring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>].</li><li>Women with overt hypothyroidism taking LT4 pre-pregnancy may need an increase in LT4 by 25–50%, depending on the aetiology of hypothyroidism and the pre-pregnancy TSH level [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>].</li><li>The ATA guidelines note that one option is to increase the daily dose of LT4 by approximately 25–30% as soon as pregnancy is suspected. In women with overt hypothyroidism, the increased requirement for  LT4 occurs as early as 4–6 weeks' gestation. Such requirements gradually increase through 16–20 weeks of pregnancy and plateau thereafter until the time of delivery. It notes that pregnant women with hypothyroidism, subclinical hypothyroidism, or those at risk of hypothyroidism need frequent monitoring of TFTs, particularly during the first half of pregnancy when there is increased demand for T4 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>The ATA guidelines also note that treatment of subclinical hypothyroidism in pregnancy with LT4 may reduce the risk of adverse pregnancy outcomes in some women, particularly those with positive thyroid peroxidase antibodies (TPOAbs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>]. This contrasts with a meta-analysis of 18 studies at low-to-moderate risk of bias (n = 3995 women), which found a lack of evidence regarding the effect of LT4 replacement therapy in pregnant women with subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Maraka, 2016</a>].</li></ul></li></ul><!-- end field 4dab0ec2-4fab-4e0d-8805-05e07939bac3 --><!-- end item 6018a63c-4aa2-45e9-bace-a3ddc163046a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}